Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2016 - 2025)

Vanda Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 141229000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 2796.41% to 141229000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 220490000.0, a 1067.73% decrease, with the full-year FY2025 number at 220474000.0, down 1066.53% from a year prior.
  • Income from Continuing Operations hit 141229000.0 in Q4 2025 for Vanda Pharmaceuticals, down from 22586000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for VNDA hit a ceiling of 9604000.0 in Q2 2021 and a floor of 141229000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 9877900.0 across 5 years, with a median of 1131500.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 1856.46% in 2021 and later tumbled 4000.73% in 2024.
  • Tracing VNDA's Income from Continuing Operations over 5 years: stood at 7098000.0 in 2021, then fell by 3.34% to 6861000.0 in 2022, then tumbled by 134.98% to 2400000.0 in 2023, then plummeted by 103.17% to 4876000.0 in 2024, then tumbled by 2796.41% to 141229000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VNDA at 141229000.0 in Q4 2025, 22586000.0 in Q3 2025, and 27207000.0 in Q2 2025.